Press Release | May 24, 2023
Pyxis Oncology to Acquire Apexigen
Read More
Press Release | May 22, 2023
Freenome Acquires Global Immunodiagnostics Developer Oncimmune Ltd
Read More
Press Release | May 19, 2023
Metagenomi to Present New Data for Its Novel Gene-Editing Systems at the 26th American Society of Gene + Cell Therapy (ASGCT) Annual Meeting
Read More
Press Release | May 19, 2023
Orchard Therapeutics Announces Positive Clinical and Preclinical Data in Programs Targeting Neurometabolic and CNS Disorders at ASGCT
Read More
News | May 16, 2023
Cyrus Bio Scientist Erik Procko and the company’s lead ACE2-Fc Fusion protein COVID-19 therapeutic are featured in Science news article
Read More
Press Release | April 27, 2023
Foresight Diagnostics announces $58.75 Million Series B financing led by Foresite Capital to commercialize ultrasensitive liquid biopsy MRD testing platform
Read More
Press Release | April 26, 2023
Orbital Therapeutics Secures $270 Million in Series A Financing to Unleash Full Potential of RNA Medicines
Read More
Press Release | April 18, 2023
ImCheck Achieves the Primary Objectives of Phase I of the EVICTION-2 Trial of ICT01 in Combination with Low Dose IL-2, Data Presented at AACR 2023
Read More
Press Release | April 13, 2023
Caris Life Sciences and Flare Therapeutics Announce Strategic Preferred Portfolio Partnership to Advance Flare’s Precision Oncology Pipeline
Read More
News | March 26, 2023
Investing long-term in the cell & gene therapies of the future
Read More
News | March 22, 2023
Flare Therapeutics Announces Oversubscribed $123 Million Series B Financing
Read More
Press Release | March 16, 2023
Pyxis Oncology Announces Dosing of First Subject in Phase 1 Trial of PYX-201, a Novel ADC for Solid Tumors
Read More
News | March 15, 2023
Passage of FDA Modernization Act 2.0 Opens Opportunities for New Alternative Methods in Drug Development
Read More
Press Release | March 13, 2023
Pliant Therapeutics Announces Positive DSMB Safety Review and Initiation of Enrollment of Phase 2a Trial of Bexotegrast (PLN-74809) at 320 mg Dose in Primary Sclerosing Cholangitis
Read More
Press Release | March 9, 2023
Palvella Therapeutics Announces Positive Topline Results from Phase 2 Study of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations, a Serious, Rare Genetic Skin Disease with No FDA-approved Therapies
Read More
News | March 7, 2023
Carisma Therapeutics Closes Merger with Sesen Bio
Read More
Press Release | March 6, 2023
Orchard Therapeutics Announces Strategic Financing Totalling up to $188 Million
Read More
Press Release | March 3, 2023
Affini-T Therapeutics to Present Data from Lead Oncogenic Driver Candidate at AACR Special Conference: Targeting RAS
Read More
Press Release | March 2, 2023
Metagenomi Recognized as One of World’s Most Innovative Companies by Fast Company
Read More
Press Release | March 1, 2023
DICE Therapeutics Announces Late-Breaking Presentation at the 2023 American Academy of Dermatology (AAD) Annual Meeting
Read More
News | February 27, 2023
Pathway to Cures Appoints Investment Committee
Read More
Press Release | February 2, 2023
Pliant Therapeutics Announces FDA Clearance of Investigational New Drug Application for PLN-101095, A Novel Integrin Inhibitor for the Treatment of Solid Tumors
Read More
Press Release | February 1, 2023
Dr. Joseph E. Eid, Who Led Merck’s Pioneering Clinical Development of KEYTRUDA®, joins Dragonfly Therapeutics as President of R&D
Read More
Press Release | January 31, 2023
Carisma Therapeutics Appoints Leading Solid Tumor Immunotherapy Expert Padmanee Sharma, MD, PhD to Scientific Advisory Board
Read More
Press Release | January 27, 2023
Pliant Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
Read More
Press Release | January 22, 2023
Pliant Therapeutics Announces Positive Data from the INTEGRIS-IPF Phase 2a Trial Demonstrating Bexotegrast 320 mg was Well Tolerated and Achieved Statistically Significant FVC Increase in Patients with Idiopathic Pulmonary Fibrosis
Read More
Press Release | January 18, 2023
Freenome Partners with Geisinger for the Sanderson Study
Read More
Education | January 12, 2023
Agent Capital’s Associate, Jonathan Ark’s PhD Work Published in Cell
Read More
Press Release | January 11, 2023
Zenas BioPharma Announces First Patient Dosed in Phase 3 Clinical Study of Obexelimab for the Treatment of Immunoglobulin G4-Related Disease (IgG4-RD)
Read More
Press Release | January 9, 2023
Orchard Therapeutics Highlights Recent Progress Across HSC Gene Therapy Portfolio and Outlines Key 2023 Milestones
Read More
Press Release | January 6, 2023
Dragonfly Therapeutics Announces Sixth Dragonfly TriNKET Opt-in by Bristol Myers Squibb
Read More
Press Release | January 6, 2023
Precision BioSciences Receives Favorable Type C Feedback from the FDA on the Company’s Chemistry, Manufacturing, and Controls (CMC) Strategies for Late-Stage Development of Azercabtagene Zapreleucel, its Lead Allogeneic CAR T Clinical Candidate
Read More
Press Release | January 5, 2023
Palvella Therapeutics Announces Series D Financing of Up to $37.7 Million to Accelerate Late-Stage Development and Support Commercialization of Novel Therapies for Serious, Rare Genetic Skin Diseases
Read More
Press Release | January 5, 2023
Orchard Therapeutics Announces U.S. FDA Clearance of IND Application for OTL-203 in MPS-IH
Read More
Press Release | January 5, 2023
Metagenomi Closes Oversubscribed Series B Financing Totaling $275M to Advance Lead Therapeutic Programs into Clinical Development and Grow Genetic Medicines Pipeline
Read More
News | January 4, 2023
Top Life Sciences Startups to Watch in 2023
Read More
Press Release | January 4, 2023
Immunitas Therapeutics Announces First Patient Dosed in Phase 1/2a Study of IMT-009
Read More
News | January 3, 2023
Viewpoint: Expanding TRIPS waiver is bad for innovation
Read More
News | December 15, 2022
Metagenomi Announces Publication of Data in Nature Communications Describing Novel, Ultra-Small Nucleases for Gene Editing
Read More
Press Release | December 15, 2022
Pliant Therapeutics Receives Orphan Designation from the European Medicines Agency for Bexotegrast (PLN-74809) for the Treatment of Idiopathic Pulmonary Fibrosis
Read More
Press Release | December 12, 2022
Orchard Therapeutics Announces Promising Early Neurocognitive Outcomes from Ongoing Proof-of-concept Study of OTL-201 in MPS-IIIA
Read More
Press Release | December 12, 2022
Freenome Presents Research Highlighting The Promise of Identifying Drug-Response Biomarker for DLBCL Patients
Read More
Press Release | December 8, 2022
Vertex and Entrada Therapeutics Establish Collaboration to Discover and Develop Endosomal Escape Vehicle (EEV) Therapeutics for Myotonic Dystrophy Type 1 (DM1)
Read More
Press Release | December 8, 2022
Dragonfly Therapeutics Announces First Patient Dosed in Phase 1 Study of its EGFR-targeting TriNKET™
Read More
Press Release | November 24, 2022
Proud to congratulate ImCheck’s scientific founder, Prof. Daniel Olive, on his election as President of the French Society of Immunology
Read More
Press Release | November 15, 2022
ElevateBio and Affini-T Therapeutics Announce Partnership to Advance Affini-T’s T Cell Therapy Programs Targeting Core Oncogenic Drivers
Read More
News | November 14, 2022
Ionis, Metagenomi pen Big Pharma-sized genetic target pact that could total almost $3B
Read More
Press Release | November 11, 2022
ImCheck Presents Initial Patient Data from the EVICTION-2 Clinical Trial at SITC Annual Meeting
Read More
Press Release | November 7, 2022
Affini-T Therapeutics to Present Preclinical Data from its Lead Programs Targeting KRAS G12V at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
Read More
Press Release | November 7, 2022
Zenas BioPharma Secures $118 Million to Advance Its Broad Pipeline of Autoimmune Disease Therapeutics
Read More
Press Release | November 1, 2022
Dragonfly Announces First Patient Dosed in Clinical Trial with Merck Evaluating Solid Tumor Target
Read More
Press Release | October 11, 2022
DICE Therapeutics Announces Positive Topline Data from Phase 1 Clinical Trial of Lead Oral IL-17 Antagonist, DC-806, for Psoriasis
Read More
Press Release | October 3, 2022
Metagenomi Announces Opening of Manufacturing Facility for its Next Generation CRISPR Gene-Editing Systems and Therapies
Read More
News | September 22, 2022
Affini-T Therapeutics Named to the 2022 Endpoints 11
Read More
News | September 22, 2022
Metagenomi Named an Endpoints 11 Winner
Read More
News | September 21, 2022
Sesen Bio and Carisma Therapeutics Announce Merger Agreement
Read More
Press Release | September 10, 2022
ImCheck Presents Positive Safety and Efficacy Data from the Completed Phase 1 Dose Escalation Cohort of ICT01 plus Pembrolizumab in the EVICTION Trial at ESMO Congress 2022
Read More
Press Release | September 1, 2022
Pliant Therapeutics Announces Positive DSMB Safety Review of INTEGRIS-IPF Phase 2a Trial of PLN-74809 at 320 mg Dose in Idiopathic Pulmonary Fibrosis
Read More
Press Release | July 26, 2022
Affini-T Therapeutics Appoints Pioneering T Cell Therapy and KRAS Developer Dirk Nagorsen, M.D., as Chief Medical Officer
Read More
Press Release | July 11, 2022
Pliant Therapeutics Announces Positive Safety and Efficacy Data from Phase 2a INTEGRIS-IPF Clinical Trial of PLN-74809 in Patients with Idiopathic Pulmonary Fibrosis
Read More
Press Release | July 5, 2022
Skyhawk Announces Collaboration Agreement with Sanofi for Oncology and Immunology Targets
Read More
Press Release | June 21, 2022
Carbon Biosciences Launches with $38 Million Series A Financing to Advance Novel Gene Therapy Platform and Pipeline
Read More
Press Release | June 13, 2022
ImCheck Closes Upsized EUR 96 Million (USD 103 Million) Financing to Advance Clinical Program of First-in-human Gamma-delta T Cell Activating Antibody and Accelerate Development of Disruptive Immunotherapeutic Pipeline
Read More
Press Release | May 15, 2022
Zenas BioPharma Submits Investigational New Drug Application in China for ZB001 for the Treatment of Thyroid Eye Disease
Read More
Press Release | May 2, 2022
Gilead follows Big Pharma peers to Dragonfly’s pond in $300M deal for natural killer cell engagers
Read More
Press Release | April 20, 2022
Dragonfly Therapeutics Announces Multi-Target Expansion of its Research Collaboration with AbbVie to Develop Novel Therapeutic Candidates for Immune-Mediated Diseases
Read More
Press Release | April 8, 2022
ImCheck Provides Updated ICT01 and Pembrolizumab Combination Data from the Phase I/IIa EVICTION Trial at AACR Annual Meeting 2022
Read More
Press Release | April 8, 2022
Pyxis Oncology Announces Preclinical Data on Anti-Siglec-15 BSI-060T (PYX-106) Presented by Biosion, Inc. at the 2022 American Association for Cancer Research (AACR) Annual Meeting
Read More
News | March 22, 2022
Affini-T Therapeutics Completes $175 Million Financing Co-Led by Vida Ventures and Leaps by Bayer to Advance Groundbreaking T Cell Therapies for Solid Tumor Patients with Oncogenic Driver Mutations
Read More
Press Release | March 1, 2022
Dragonfly Therapeutics Announces Achievement of Phase 1 Clinical Development Milestone for IL-12 Investigational Immunotherapy Program with Bristol Myers Squibb
Read More
Press Release | February 28, 2022
Freenome Launches the Vallania Study for the Early Detection of Multiple Cancers
Read More
News | February 28, 2022
Aptinyx Completes Enrollment in Phase 2b Study of NYX-2925 in Fibromyalgia
Read More
Press Release | February 24, 2022
Pliant Therapeutics Announces Positive DSMB Safety Review and Commencement of Enrollment of Phase 2a Trial of PLN-74809 at 320 mg Dose in Idiopathic Pulmonary Fibrosis
Read More
Press Release | February 3, 2022
Orchard Therapeutics Announces Historic Agreement Making Libmeldy Available by NHS England for MLD Patients
Read More
News | January 28, 2022
Cyrus Biotechnology CEO Lucas Nivon featured in Fierce Biotech Webinar
Read More
News | January 25, 2022
Metagenomi Closes Oversubscribed $175M Series B Financing to Advance Therapeutic Pipeline and Expand Novel Gene Editing Platform
Read More
Press Release | January 19, 2022
Orbus Therapeutics’ Phase 3 Eflornithine STELLAR Study Reaches Full Patient Enrollment
Read More
Press Release | January 6, 2022
Zenas BioPharma Appoints Dr. John Orloff to Board of Directors
Read More
News | December 16, 2021
Verge Genomics Secures $98 Million in New Financing
Read More
Press Release | December 9, 2021
Interius BioTherapeutics Announces Granting of US Patent to Support in Vivo Cell-Specific Gene Delivery Platform
Read More
News | December 1, 2021
Entrada Therapeutics: Advancing A New Class Of Medicines Called EEV
Read More
News | December 1, 2021
Cyrus Biotechnology
Read More
News | December 1, 2021
Zenas BioPharma
Read More
Press Release | November 23, 2021
Dragonfly Announces Merck Opt-In on Second TriNKET
Read More
News | November 12, 2021
ImCheck Provides Promising Updated Patient Response Data from the Phase I/IIa EVICTION Trial with ICT01 at SITC Meeting 2021
Read More
News | October 20, 2021
imCheck Publishes Comprehensive Overview of the Developmenet Resumts of its First-in-class Cancer Immunotherapeutic Targeting BTN3A to Activate Cells in Science Translational Medicine
Read More
Press Release | October 18, 2021
Dragonfly Therapeutics Announces Sixth Dragonfly Drug to be Licensed by Bristol Myers Squibb and Receipt of Milestone Payments Following First Patient Dosing of Two TriNKET™ Immunotherapies
Read More
Press Release | October 13, 2021
Agent Capital Adds Dr. John Orloff as Venture Partner
Read More
Press Release | October 11, 2021
Pyxis IPO leads way as four life science firms kick off 4Q, raising nearly $500M
Read More
Press Release | October 8, 2021
Pyxis Oncology Raises $168M in Upsized IPO
Read More
Press Release | October 8, 2021
Precision BioSciences Statement on Safety of its Allogeneic CAR T Cells
Read More
Press Release | October 4, 2021
New Study Finds Freenome’s Multiomics Approach Successful in Detecting Pancreatic Cancer
Read More
Press Release | October 4, 2021
Research Highlights Freenome’s Blood Test for Colorectal Cancer to Primary Care Physicians
Read More
Press Release | October 1, 2021
ImCheck to Present Updated Patient Response Data from the EVICTION Trial and Additional ICT01 Results at the SITC Annual Meeting 2021
Read More
News | September 28, 2021
Orbus Therapeutics Granted European Patent for Method of Use for Eflornithine
Read More
News | September 17, 2021
Skyhawk Therapeutics Completes New Investment Round
Read More
News | September 17, 2021
DICE Therapeutics Announces Pricing of Upsized Initial Public Offering
Read More
News | September 17, 2021
ImCheck Presents Preliminary Patient Response Data from the Phase I/IIa EVICTION Trial with ICT01 at ESMO Congress 2021
Read More
News | September 14, 2021
Bill Haney adds another $133M to Skyhawk’s coffers, as the RNA startup guns for the clinic
Read More
Press Release | September 14, 2021
Skyhawk Therapeutics Completes New Investment Round
Read More
Press Release | September 8, 2021
Immunitas Therapeutics Appoints Seng-Lai ‘Thomas’ Tan, Ph.D. as Chief Scientific Officer
Read More
Press Release | August 18, 2021
Immunitas Therapeutics Completes $58 Million Series B Financing to Advance Pipeline into the Clinic and Expand Single Cell Analysis Drug Development Platform for Immuno-Oncology and Other Diseases
Read More
News | July 13, 2021
ImCheck Publishes Seminal Paper in Cell Reports Elucidating How Butyrophilins Activate Vγ9Vδ2 T cell Function Against Tumor Cells
Read More
News | June 1, 2021
Alloy Therapeutics and Pyxis Oncology Form Kyma Therapeutics to Develop Novel Immune-Modulating Antibodies for Cancer and Autoimmune Diseases
Read More
News | May 18, 2021
Interius BioTherapeutics Raises $76M Series A Financing to Advance Breakthrough Cell and Gene Therapy Platform
Read More
Press Release | March 31, 2021
Entrada Therapeutics Announces Closing of $116 Million Series B Financing
Read More
Press Release | March 30, 2021
Pyxis Oncology Closes $152 Million Series B Financing to Further Advance Portfolio of Biologics
Read More
Press Release | March 18, 2021
Pyxis Oncology Announces Worldwide Licensing Agreement with Pfizer to Develop and Commercialize Multiple Antibody-Drug Conjugates
Read More
News | March 18, 2021
CAR-M era begins as Carisma doses first patient
Read More
News | January 8, 2021
DiCE gets its ‘library’ card ready as it speeds development of DNA database-derived molecules with more investor cash
Read More
News | January 7, 2021
CARISMA Therapeutics Completes Series B Funding to Advance Development of Novel CAR-Macrophage Immunotherapies
Read More
Press Release | December 21, 2020
Orchard Therapeutics Receives EC Approval for Libmeldy™ for the Treatment of Early-Onset Metachromatic Leukodystrophy (MLD)
Read More
News | November 20, 2020
Lilly, Precision Biosciences team up on Duchenne gene therapy in $135M deal
Read More
Press Release | November 5, 2020
Orchard Therapeutics Announces New OTL-201 Clinical Data in Sanfilippo Syndrome Type A (MPS-IIIA) Accepted for Oral Presentation at 62nd American Society of Hematology Annual Meeting
Read More
News | November 3, 2020
Orbus Therapeutics Publishes in Oncotarget Scientific Journal
Read More
Press Release | October 22, 2020
Orbus Therapeutics Expands Series A Financing to $71 Million to Support Ongoing STELLAR Phase 3 Study in Rare Brain Cancer
Read More
Press Release | October 19, 2020
Aptinyx Reports Positive, Statistically Significant, Top-line Data From Phase 2 Study of NYX-783 in Patients With Post-Traumatic Stress Disorder
Read More
Press Release | October 15, 2020
Precision BioSciences Announces U.S. Patent Trial and Appeal Board Upholds Allogeneic CAR T Patents
Read More
Press Release | October 14, 2020
ImCheck Announces Four ICT01 Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer 35th Anniversary Annual Meeting
Read More
Press Release | October 9, 2020
Geeta Vemuri named Top 100 Powerful Women of 2020 by Entrepreneur
Read More
News | October 1, 2020
Skyhawk Therapeutics Named Top 11 Biotech Startup 2020 by Endpoints News
Read More
Press Release | September 17, 2020
Precision BioSciences and Servier Expand CAR T Oncology Development Collaboration with Four New Programs Targeting Hematological and Solid Tumors
Read More
Press Release | September 10, 2020
ImCheck Achieves Initial Positive Independent Safety Review and Initiates Next Stage of Phase I/IIa EVICTION Trial for ICT01. Company Receives FDA Approval for US IND
Read More
News | August 26, 2020
Freenome Closes $270 Million Series C Financing to Advance Novel Multiomics Blood Testing Platform for Early Cancer Detection
Read More
News | August 17, 2020
BMS Licenses IL-12 from Dragonfly in $475 Million Upfront Deal
Read More
News | July 29, 2020
Women in Bio: Geeta Vemuri Blazes a Trail in Venture Capital
Read More
Press Release | July 27, 2020
CARISMA Therapeutics Announces FDA Clearance of IND Application for First-Ever Engineered Macrophage Immunotherapy
Read More
News | July 23, 2020
Clearing the Hurdles to a Career in Venture Capital; An Interview with Geeta Vemuri
Read More
Press Release | July 16, 2020
Agent Capital Expands Management Team; Appoints Jacopo Leonardi as Partner
Read More
Press Release | July 15, 2020
Orchard Therapeutics Announces Global License Agreements for Stable Cell Line Technology from GSK
Read More
Press Release | July 9, 2020
ImCheck Therapeutics Appoints Claude Knopf as Chief Business Officer
Read More
Press Release | July 9, 2020
Orchard Therapeutics and MolMed Announce Extension of Gene Therapy Manufacturing Collaboration
Read More
Press Release | July 8, 2020
Precision BioSciences Announces Dosing of First Patient in Phase 1/2a Clinical Trial of PBCAR269A for Multiple Myeloma
Read More
News | July 6, 2020
Bristol Myers Pays Dragonfly $55M to Bring NK Cells to Neuro Diseases
Read More
Press Release | July 6, 2020
Precision BioSciences Regains Rights to In Vivo Hepatitis B Virus Program
Read More
Press Release | June 26, 2020
Aptinyx to be Added to Russell 2000® Index
Read More
Press Release | June 18, 2020
Aptinyx Completes Enrollment in Phase 2 Exploratory Study of NYX-783 in Post-Traumatic Stress Disorder
Read More
News | June 3, 2020
Biotech Pliant Therapeutics pulls off $144M IPO to advance fibrosis pipeline
Read More
Press Release | May 28, 2020
Palvella Therapeutics Completes $45 Million Series C Financing
Read More
Press Release | May 26, 2020
Freenome Announces Initiation of the PREEMPT CRC Clinical Trial for the Early Detection and Prevention of Colorectal Cancer Using a Multiomics Blood Test
Read More
Press Release | May 19, 2020
HalioDx to Characterize the Immune Contexture of Patients Enrolled in ImCheck’s EVICTION Phase 1/2 Clinical Trial
Read More
Press Release | May 15, 2020
New Data from Carisma Therapeutics Uncover Potential of Expedited Pathway for Immunotherapy Development Through CAR Monocytes
Read More
Press Release | May 15, 2020
Orchard Therapeutics Presents New Interim Data from OTL-203 Proof-of-concept Study for MPS-I
Read More
News | May 12, 2020
Merck doubles down on Skyhawk’s tech to drug RNA, promising $600M per autoimmune, metabolic target
Read More
News | March 31, 2020
Latest Penn biotech spinout taking on cancer raises $1.6M from investors
Read More
Press Release | March 26, 2020
First Patient Dosed in EVICTION Trial Evaluating ImCheck’s Lead Anti-Cancer Drug, ICT01: A Novel Gamma Delta T Cell-Activating Immunotherapy
Read More
News | March 23, 2020
First-of-its-kind Engineered Macrophage Cell Therapy Platform Shows Ability to Reduce Tumor Burden and Activate Anti-Tumor Immunity, Improving Overall Survival in Pre-Clinical Cancer Models
Read More
Press Release | March 23, 2020
Pliant Therapeutics Initiates First-in-Human Clinical Trial of PLN-1474 for the Potential Treatment of Liver Fibrosis
Read More
Press Release | March 17, 2020
ImCheck Therapeutics Expands Leadership Team with Appointment of Hans Henrik Chrois Christensen as Chief Financial Officer and Chief Operating Officer
Read More
Press Release | March 3, 2020
Pliant Therapeutics Raises $100 Million in Series C Financing to Advance Therapies for Fibrotic Diseases
Read More
News | January 23, 2020
Business Wire Freenome Announces Encouraging Performance Data for Its Multiomics Blood Test to Detect Early-Stage Colorectal Cancer in a Prospective, Multi-Center Clinical Study
Read More
Press Release | January 8, 2020
Entrada Therapeutics Announces ENTR-501 for the Treatment of Mitochondrial Neurogastrointestinal Encephalomyopathy (MNGIE)
Read More
Press Release | January 6, 2020
Carisma Therapeutics Expands Leadership Team
Read More
Press Release | December 4, 2019
ImCheck Raises $53 Million Series B to Advance Clinical Pipeline of Novel Gamma Delta T-Cell-Focused Antibodies for Cancer and Autoimmune Diseases
Read More
Press Release | November 8, 2019
Precision BioSciences Announces the Presentation of Initial Clinical Data Supporting the Safety and Clinical Activity of PBCAR0191, a Novel CD19 Targeted Allogeneic CAR T Therapy Candidate, at the American Society of Hematology Annual Meeting
Read More
Press Release | November 6, 2019
Orchard Therapeutics to Present New Registrational Data of Investigational Gene Therapies at the 61st American Society of Hematology Annual Meeting
Read More
Press Release | October 28, 2019
Aptinyx Announces Results of Phase 2 Fibromyalgia Study of NYX-2925 Have Been Selected for Late-Breaking Presentation at the American College of Rheumatology Annual Meeting
Read More
News | October 23, 2019
Novartis bets $80M on Pliant’s preclinical NASH prospect
Read More
News | July 19, 2019
Pyxis Oncology Raises $22 Million Series A
Read More
News | July 16, 2019
Genentech inks its latest discovery deal — this time turning to RNA upstart Skyhawk
Read More
News | July 8, 2019
Fattening the bankroll, Bill Haney adds cancer R&D powerhouse Merck to Skyhawk’s roster of partners out to drug RNA
Read More
News | June 10, 2019
Aptinyx Reports Top-line Data from Phase 2 in Patients with Fibromyalgia
Read More
News | June 3, 2019
Carisma Therapeutics Names Dr. Robert Petit As Chief Scientific Officer
Read More
News | May 27, 2019
Carisma Therapeutics Featured in Nature Biotechnology’s Top Academic Spin-outs 2018
Read More
Press Release | May 14, 2019
Precision BioSciences Appoints Christopher R. Heery, M.D., as Chief Medical Officer
Read More
Press Release | May 6, 2019
Skyhawk Therapeutics Announces Agreement with Takeda for Neurodegenerative Diseases
Read More
News | April 9, 2019
Pliant Therapeutics Reports Positive Results Of Phase 1 Clinical Study
Read More
News | March 1, 2019
Genome editing company Precision proposes $100M IPO
Read More
News | January 16, 2019
Aptinyx Reports Top-line Results from Phase 2 Clinical Study of NYX-2925 in Painful Diabetic Peripheral Neuropathy
Read More
Press Release | January 4, 2019
Biogen and Skyhawk Therapeutics Announce Agreement to Develop Novel Small Molecule RNA Splicing Modifiers for Neurological Disease Targets
Read More
News | January 3, 2019
Pliant Therapeutics Initiates Phase 1 Clinical Study of PLN-74809
Read More
News | December 18, 2018
Palvella Therapeutics Announces $10 Million in Funding from Ligand Pharmaceuticals to Accelerate PTX-022 through Phase 2/3 Clinical Study in Pachyonychia Congenita
Read More
Press Release | December 18, 2018
Entrada Therapeutics Raises $59 Million Series A to Advance Intracellular Biologics Platform
Read More
Press Release | December 13, 2018
Orchard Therapeutics Announces the Build-out of New Gene Therapy Manufacturing Facility in California
Read More
Press Release | December 6, 2018
Precision BioSciences and Durham STEM Students Lead Launch of First Genome Editing Experiment Into Space
Read More
News | November 27, 2018
Precision BioSciences Receives FDA Authorization to Initiate Clinical Study of Gene Edited Cancer Immunotherapy
Read More
News | November 20, 2018
Pliant Therapeutics Receives FDA Orphan Drug Designation for Lead Program PLN-74809 in Primary Sclerosing Cholangitis
Read More
News | November 5, 2018
Orchard Therapeutics Announces Closing of $225 Million Initial Public Offering
Read More
Press Release | July 16, 2018
Pliant Therapeutics Raises $62 Million in Series B Financing
Read More
Press Release | July 16, 2018
Verge Genomics Announces $32 Million Series A
Read More
News | June 27, 2018
Carisma Nabs $53 Million Series A for Cellular Cancer Therapy
Read More
Press Release | June 26, 2018
Skyhawk Therapeutics Announces $40 Million Equity Investment Round
Read More
News | June 26, 2018
Kauffman Fellows Celebrates Its Most Diverse Group of Talented Leaders With Class 23
Read More
News | June 26, 2018
Genome Editing Startup Precision BioSciences Scores $110 Million Series B
Read More
Press Release | June 26, 2018
Precision BioSciences Raises $110M
Read More
News | June 26, 2018
Skyhawk Therapeutics Gains $100 Million Through Venture Round, Collaboration
Read More
News | June 26, 2018
CAR Macrophage Tumor Tech Created by UPenn Star Scientists Gets $53M
Read More
Press Release | June 20, 2018
Aptinyx Announces Pricing of Initial Public Offering
Read More
News | April 12, 2018
UK Gene Therapy Firm Orchard Plans Stock Offer After GSK Deal
Read More
Press Release | December 20, 2017
Orchard Therapeutics Announces $110M Series B Financing
Read More
Press Release | December 18, 2017
Aptinyx Raises $70 Million in Series B Financing
Read More